On-Treatment Low Serum HBV RNA Level Predicts Initial Virological Response in Chronic Hepatitis B Patients Receiving Nucleoside Analogue Therapy
Antiviral Therapy2014Vol. 20(4), pp. 369–375
Citations Over TimeTop 21% of 2014 papers
Yi‐Wen Huang, Shoichi Takahashi, Masataka Tsuge, Chi‐Ling Chen, Ting‐Chuan Wang, Hiromi Abe, Jui-Ting Hu, Ding‐Shinn Chen, Sien-Sing Yang, Kazuaki Chayama, Jia‐Horng Kao
Abstract
Low serum HBV RNA level at week 12 of nucleoside analogue therapy independently predicts initial virological response in treated chronic hepatitis B patients. Serum HBV RNA levels may thus be useful for optimizing treatment of chronic hepatitis B.
Related Papers
- → Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir(2008)25 cited
- → Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: Outcome at 2 Years(2011)14 cited
- → Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance(2009)13 cited
- → The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis(2016)5 cited
- → The High Incidence of the Emergence of Entecavir-Resistant Mutants among Patients Infected with Lamivudine-Resistant Hepatitis B Virus(2007)9 cited